While antigens for CAR-T cells in hematologic malignancies, most notably CD19 in B-cell malignancies and B-cell maturation antigen (BCMA) in multiple myeloma, are selectively expressed on target cancer cells and their cells of origin, targetable antigens in solid tumors are more elusive. This evidence concerns the gene TNFRSF17 and cancer.